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The cellular transactivator Brn-3a has previously been shown to be expressed at elevated levels in the cervix of women with
squamous cell carcinoma of the cervix (SCC) and to activate the expression of HPV E6 mRNA. In this study, we show that common
and rare cervical precancer lesions, including those of adenocarcinoma (AC), which are usually diﬃcult to diagnose using classical
procedures, also expressed high levels of Brn-3a and can be diagnosed by measuring the levels of Brn-3a and E6 mRNAs.
Copyright © 2009 Daniel Ndisang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Cervical cancer is the second most common gynaecological
cancer worldwide, with developing countries having the
highest incidence [1]. Of the approximately 0.5 million new
cases reported worldwide each year, over a quarter of a mil-
lion are from Asia, with Latin America and Africa accounting
for more than an eighth of a million cases [2–4]. In developed
countries, cervical cancer screening programmes have helped
to reduce the incidence of some of the common cervical
ailments such as squamous cell carcinoma (SCC) [1–4], but
not of cervical adenocarcinoma (AC) which is rapidly on
the increase [5–7], or the rare sarcomatoid squamous cell
carcinoma (SSCC) whose prognosis is very poor [8–11].
Unfortunately, in developing countries such as Brazil,
cervical cancer screening programmes are too costly. As a
result, unsuitable less costly cervical programmes are often
put into place, thus mortality rates due to AC and other
associated cervical ailments have been on the increase [12–
14], and this is a common universal public health problem
across the developing world [9, 10].
It is therefore imperative for appropriate and cost-
eﬀective diagnostic programmes which could detect the early
onset of AC, SCC, and SSCC to be made available in both
the developed and developing worlds [5–7, 15–17], thereby
reducing the huge cost of cervical treatment and palliative
programmes which is adversely aﬀecting the public health
policies of these countries [3, 15, 16, 18].
Interestingly, several studies have portrayed HPV as
a pivotal aetiological agent in AC [5–10, 19, 20], and
WHO has also indicated HPV as the primary cause of
SCC and associated cervical ailments [1, 5–10]. Moreover,
some of these studies have shown that, AC, SCC, and even
SSCC shared a similar aetiological profile that depends on
the expression of the oncogenic early-open-reading frame
(EORF) E6/E7 products of HPV [3, 5–7, 9, 10].
Although studies have suggested that HPV could be
the main aetiological determinant for AC and SCC [5–7],
others have suggested environmental factors and/or genetic
predisposition [8]. Nevertheless, over 90% of AC could be
associated to HPV [3–6], and a very small percentage, could
potentially be attributed to environmental cofactors such as
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smoking or medication such as oral contraceptives, or even
the impact of other sexual transmitted diseases (STD) [6, 7].
Many studies have shown that HPV depends on its
EORF E6/E7 oncoproteins [21–24] to transform cervical
cells. Interestingly, cellular factors bind specific motifs of
the viral URR (upstream regulatory region) to regulate the
production of these oncoproteins. Brn-3a is a member of the
POU family of transcription factors, expressed in cervical
cells, and whose presence is closely associated with HPV
mRNA positivity. [25–29]. We have previously shown that
measurement of Brn-3a mRNA levels in cervical smears
using our simple noninvasive cost-eﬀective procedure has
considerable potential in screening and diagnosis of cervical
neoplasia in both developing and developed countries [18,
30–32].
In addition, several of our studies have shown not only
that Brn-3a mRNA is elevated uniformly in the cervix
of women with cervical ailments [33], but also that this
elevation directly correlates with HPV activity and disease
progression in the aﬀected region where HPV is present [18,
27, 33]. This is because Brn-3a transactivates the HPV URR
and the transcribed EORF E6 product is crucial for cervical
transformation [27–29]. For instance, cervical carcinoma
precursor lesions such as those of SCC and AC, which are
frequently situated in the innermost regions of the cervix [6,
7], where it is always diﬃcult to exfoliate cells for diagnosis
using classical tools [6, 7, 34], could potentially be diagnosed
using the mRNA levels of Brn-3a as well as HPV. This is
because the oncogenic gene products of HPV, E6, and E7
depend on the activity of specific cellular transactivators such
as Brn-3a for its transactivation [6, 18, 30–32].
Importantly, the level of E6 mRNA, which parallels that
of Brn-3a in cervical scrapes, has previously been shown
to have considerable potential in screening and diagnosis
of cervical abnormalities [18, 30–32]. Moreover, because of
the cost-eﬀectiveness of measuring Brn-3a and E6, it could
therefore be of particular importance in countries where cost
is hampering cervical programmes [13, 16, 18, 34] or where
classical procedures are inadequate in diagnosing the early
stages of these diseases [6, 12, 31, 34].
Here we report that the cellular transcription factor
Brn-3a measured from cervical scrapes of women with
AC and SCC precancer lesions can potentially be used for
the screening and diagnosing of AC and SCC. This is the
first time in which the activity of the primary aetiological
agent of two diﬀerent types of cervical cancer has been
evaluated on the basis that the cellular factor, which regulates
production of its oncogenic transforming proteins [27, 35],
is a logical and cost-eﬀective target that could be used for
the diagnosing, controlling, and managing of these cancers
[18, 32].
2. Material and Methods
2.1. Patients. The present study comprised two diﬀerent
groups of patients. Group one is made up of patients
in Recife-Brazil a developing country, and Group two
comprises of patients in London-England in the United
Kingdom, a developed country. The study group in Recife-
Brazil, consisted of 85 women with cervical abnormali-
ties attending one of the following gynaecological units:
(1) Instituto Materno Infantil De Pernambuco (IMIP)
Recife-Pernambuco Brazil, (2) The Gynaecological Oncology
Research Unit Bar de Lucena Hospital-Recife, and (3) The
Cancer Hospital Recife. The mean age for this group was
44.8 years (the median: 42 years and the range: 21–81
years). The study group in London-England consisted of 51
women attending either the colposcopy or gynaecological
clinics at the Whittington Hospital London. The mean age
for this group was 34.7 years (median: 30.5 years and
the range: 19–61). In both groups, ethical permission was
obtained from the respective hospital’s ethics committee
after review of the study protocol. All the women in both
groups provided informed consent to obtain and use their
cervical material for the purpose of the study. Most of the
women acknowledged the desire to participate for a long-
term follow-up programme.
This study focuses on women with High-grade Cervical
Glandular Intraepithelial Neoplasia (HG CGIN) (adenocar-
cinoma (AC) precancer lesion, FIGO stages; adenocarcinoma
in situ stages 1a1 and 1a2), women with High-grade
Cervical Intraepithelial Neoplasia (HG CIN) (squamous
cell carcinoma (SCC) precancer lesion; CIN2 and CIN3),
and as our control group, women with cervicitis, which
is an inflammation of the uterine cervix usually attributed
to infection caused by sexually transmitted diseases [18].
Conversely, squamous cell carcinoma is a characteristic
malignancy that is thought to originate from the cells
that cover the ectocervix, whilst cervical adenocarcinoma
is thought to originate from malignant adenomatous or
glandular cells distributed along the endocervical canal of
the cervix [5–8]. Moreover, cervical adenocarcinoma is rare
and accounted for less than 20% of cervical cancer in women
as compared to squamous cell carcinoma which accounts
for more than 80% of this ailment [5–8]. In this study,
we also evaluate the levels of Brn-3a and HPV E6 mRNA
in sarcomatoid squamous cell carcinoma, given that it is a
very rare, aggressive, and less understood form of cervical
cancer [9]. Nonetheless, it is thought to be characterised by
biphasic tumour components of squamous cell carcinoma
and spindle cell malignancy [10]. Like the other forms of
cervical carcinomas in this study, it has also been associated
with HPV [5–10].
2.2. Study Protocol. Cervical cells were obtained and pro-
cessed using our previously described routine methodology
but with some slight modifications to reduce cost, so that
it could be conveniently adapted in developing countries
[18]. In brief, cervical scrapes were obtained using a spatula
and/or cytobrush, and the specimen was placed in 10 mL
1 X PBS and stored on ice for less than 30 minutes prior to
a 2-minute 1500 g centrifugation (in developing countries
PBS is a cheaper but eﬀective alternative to RPMI media).
The concentrated cervical cells recovered were used for RNA
extractions. The Brn-3a mRNA and HPV-16 E6 mRNA
levels were determined subsequently using our previously
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Table 1: Patients in Recife-Brazil and London-UK with rare and common forms of cervical precancer lesions plus a cervicitis control group
showing the mean mRNA levels of Brn-3a and HPV E6 in cervical scrapes.
Women from Brazil
Pathology
Case patients. Age Brn-3a mRNA HPV E6 mRNA
No. (%) Mean Mean Mean
Cervicitis 32 (38.5) 39.4 0.2a∗ 0.17∧b
SCC precancer
32 (38.5) 50.7 0.58∗ 0.55∧
∗P = .000001 P = .000002
AC precancer 17 (20.5) 44 0.47a 0.4b
aP = .00033 bP = .001
SSCC
2 (2.5) 35 <0.1† <0.1†
†0 < negligible < 0.1 †0 < negligible < 0.1
Women From England
Pathology Case patients. Age Brn-3a mRNA HPV E6 mRNA
No (%) Mean Mean Mean
Cervicitis 32 (60.4) 37.2 0.21∗ 0.17∧
SCC precancer 17 (32.1) 28.8 0.46∗ 0.30∧
∗P = .0003 ∧P = .01
AC precancer
4 (7.5) 38.5 0.46 0.41
SSCC 0 — — —
Total women in study
Pathology
Total case patients. Age Brn-3a mRNA HPV E6 mRNA
No (%) Mean Mean Mean
Cervicitis 32 + 32 (47.1) 38.3 0.20∗a 0.17∧
SCC precancer 32 + 17 (36) 39.8 0.52∗ 0.42∧
∗P = .000052 ∧P = .00046
AC precancer 17 + 4 (15.4) 41.1 0.46a 0.42b
aP = .000026 bP = .0001
SSCC
2 + 0 (1.5) 35 <0.1† <0.1†
†0 < negligible < 0.1 †0 < negligible < 0.1
described RT-PCR assay [31, 32]. To express the levels of
Brn-3a and E6 mRNA, we have taken an arbitrary scale of
values in the range of 0.0 to 1.0, with 0.0 representing a lack
of detection of mRNA and 1.0 the highest achievable level.
Importantly, the specimens used in this Material sec-
tion were not preselected according to their pathological
classifications. Indeed, the specimens were obtained by the
Clinicians and processed blindly by the Researchers.
3. Statistical Analysis
We used the linear regression model (Microsoft Excel) to
derive the coeﬃcient of regression between Brn-3a and
E6, and the correlation coeﬃcient between Brn-3a and E6
mRNA levels was derived using the Pearson Correlation
coeﬃcient (“PEARSON” in Microsoft Excel). The diﬀerences
of the mean between variables were analysed using Microsoft
Excel Student’s t-test. All other statistical analyses were
performed using Microsoft Excel. At all instances, P values
of less than .05 (P < .05) with 95% Confidence Interval (CI)
was used as the cut-oﬀ for statistical significance.
4. Results and Discussion
The levels of the mRNAs encoding the cellular transcription
factor Brn-3a and the transcribed HPV EORF E6 gene
product, measured from cervical scrapes of women in Brazil
and in England, who had a form of cervical cancer or
cervicitis (as a control group), are presented in Table 1. Of the
total of 136 cervical smears analysed from both countries, 72,
(53%) that is about one in every two, had a form of cervical
cancer. Of these, 98.6% (71/72) had significant levels of Brn-
3a and 75% (54/72) also had significant E6 (absolute R = 0.6),
(Figure 1).
Moreover, 68% (49/72) of patients have SCC precancer of
which 48/49 (97.9%) registered high Brn-3a (P = .000052)
and 33/49 (67.3%) high E6 (P = .00046) (Tables 1 and
2). Furthermore, 29% (21/72) had AC precancer with all of
them having high Brn-3a 21/21(100%) (P = .000026) and
(19/21) of them high E6 (P = .0001) (Tables 1 and 2). Two
patients in Brazil with the very rare sarcomatoid squamous
cell carcinoma showed low but detectable levels of Brn-3a
and E6, although the low level may represent a problem with
the quality of these samples.
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Table 2: Presence of Brn-3a and E6 mRNA in the cervix of women in Recife-Brazil with diﬀerent forms of cervical precancer lesions and a
cervicitis control group.
Women from Brazil
Pathology Brn-3a mRNA present HPV E6 mRNA present
(no. of cases) no. (%) no. (%)
Cervicitis (32 )
18 (56.3) 15 (46.8)
SCC precancer (32)
32 (100) 30 (93.7)
AC precancer (17)
17 (100) 15 (88.2)
SSCC (2) 2 (100) 2 (100) (%)
Women from England
Pathology Brn-3a mRNA present HPV E6 mRNA present
(no. of cases) no. (%) no. (%)
Cervicitis (32) 15 (46.8) 12 (37.5)
SCC precancer (17)
16 (94.1) 13 (76.4)
AC precancer (4)
4 (100) 4 (100)
SSCC (0) — —
Total no of pathological cases in Study
Total pathological cases in Brn-3a mRNA present HPV E6 mRNA present
study (no.) no. (%) no. (%)
Cervicitis (64) 33 (51.5) 27 (42.2)
SCC precancer (49)
48 (97.9) 33 (67.3)
AC precancer (21)
21 (100) 19 (90.4)
SSCC (2) 2 (100) 2 (100)
As expected, given that AC and SSCC constitute rare
forms of cervical cancer, 33.3% (17/51), or 1 in 3, of the spec-
imens in Brazil were AC precancer, but less than 20% (4/21)
of the specimens in England were AC precancer (Table 1).
Interestingly though, in the AC precancer specimens in
Brazil, Brn-3a was detected in 100% (17/17) of cases, while
E6 was detected in 88.2% (15/17) (Table 2). Furthermore, in
the Brazilian specimens, 32/51 (62.7%) were SCC precancer,
with Brn-3a detected in all of them 100% (32/32) and E6 in
30/32 (96.7%).
Similar prevalence was also observed with the cases in
England (Table 2), where SCC precancer registered 94.5%
(17/21) of incidence, of which 94.1% (16/17) had Brn-3a and
76.5% (13/17) had E6. Here, the AC precancer registered a
100% Brn-3a and E6 presence.
Taken together, we have demonstrated that Brn-3a and
HPV E6 mRNA were detected in the cervical scrapes of
women with diﬀerent forms of cervical precancer in both
developing and developed countries. This is in accordance
with many other studies that have suggested HPV DNA as
the primary aetiological agent for these ailments worldwide
[1–11], but also support the key role of Brn-3a in activating
HPV transcription in diﬀerent forms of cervical carcinomas.
To show that Brn-3a mRNA and the HPV E6 mRNA
correlated with one another, and could be used as a screen-
ing, diagnostic, and prognostic maker for these ailments, a
Pearson correlation coeﬃcient was performed and an r =
0.85 was obtained. Moreover, the coeﬃcient of regression
between Brn-3a and E6 for SCC and AC precancers was
respectively deduced to be R2 = 0.72 and R2 = 0.74 (Figure 1).
Thus, a clear correlation exists between the levels of the
mRNAs encoding Brn-3a and HPV E6 in diﬀerent types of
cervical lesions.
In addition, the mean values of Brn-3a and E6 in the
cervical scrapes of women with SCC and AC precancers,
SSCC and cervicitis as a control group were also determined
(Table 1 and Figure 2). The result showed that there is a
significant diﬀerence between the mean value of Brn-3a for
SCC precancer and the control group for women in Recife
(P = .000001) and for London (P = .0003), which is also
true for the E6 mean in Recife (P = .000002) and for London
(P = .01). Interestingly, a similar significant diﬀerence was
observed between the cervicitis control and the AC precancer
specimens in Recife (P = .00033) for Brn-3a and E6 (P =
.001).
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Figure 1: The scatter plot ((a) and (b)) and regression line ((c) and (d)) of Brn-3a and E6 mRNA levels in cervical scrapes obtained from
women with High-grade Cervical Intraepithelial Neoplasia (HG CIN) (squamous cell carcinoma (SCC) precancer) and High-grade Cervical
Glandular Intraepithelial Neoplasia (HG CGIN) (adenocarcinoma (AC) precancer). Note for the scatter plots, the bar designates the mean
Brn-3a and E6 mRNA levels for SCC precancer, AC precancer and cervicitis (as a control group).
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Figure 2: The mean and standard deviation of Brn-3a and E6 mRNA levels in cervical scrapes obtained from women with High-grade
Cervical Intraepithelial Neoplasia (HG CIN) (squamous cell carcinoma (SCC) precancer) and High-grade Cervical Glandular Intraepithelial
Neoplasia (HG CGIN) (adenocarcinoma (AC) precancer) and cervicitis (as a control group). Note the top bar designates the standard
deviation.
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In both Brazil and England, the mean value of Brn-3a and
E6 in the AC precancer specimens was greater than that of
the control group as depicted in Figure 2. This indicates that
women with AC and SCC precancers do have high levels of
Brn-3a that is directly reflected by the high E6 level (Figure 1,
bottom panels), thus, suggesting rapid disease progression as
compared to those who though with cervicitis, had no cancer
[18].
Taken together, this result could be of particular impor-
tance for the early diagnosing of rare and common forms
of cervical cancers, since the elevated level of Brn-3a occurs
uniformly in the cervix, and it is not confined only to the
transformation zone, so a high level of Brn-3a in the cervix
predicts rapid disease progression upon viral infection. In
agreement with this, it could therefore be employed for
predicting the early stages of AC in countries where cost is
hampering cervical screening programmes, or where classical
procedures are inadequate in diagnosing the early stages of
SCC and other related cervical diseases.
This is because, as we have shown in several studies, the
rate of transactivation of the oncogenic EORF gene product
E6 depends on the level of Brn-3a. Thus, the level of the
cellular factor Brn-3a predicts the rate of viral activity, and
hence the rate of the accelerated neoplastic transformation.
Indeed, Brn-3a measurements have been used successfully
in the past in our clinics to recall women for further
gynaecological examinations [31, 32].
However, further studies are needed to ascertain why
young women in a developed country, such as in England,
do have high prevalence of SCC precancer (mean age 28.8,
Brn-3a mean 0.46 P = .001) as compared to women in
Brazil a developing country with SCC precancer (mean age
50.7, Brn-3a mean 0.58 P = .000001) [18, 31, 32]. In
accordance with the literature [6–8, 13–16], the mean age
of AC precancer prevalence in Recife, a city in a developing
country, was higher (mean age 44, mean Brn-3a 0.47 P =
.00033) as compared to that observed in London, a city in a
developed country (age mean 38.5, mean Brn-3a 0.46) [6–
8, 13–16].
However, no correlation was observed between age and
Brn-3a level in the cervix, suggesting that the high levels
of Brn-3a in the cervix of women with cancer in both the
developing and developed countries could be due to genetic
or other environmental factors rather than hormones [22,
36], which is mostly age related [6–10]. It will be important
therefore to carry out a longitudinal study to investigate
if women who present high Brn-3a are predisposed to
accelerated neoplastic transformation in the cervix should
they be infected with HPV, since none of the prophylactic
vaccines have a life-time or 100% protection [37].
Thus, the expression of the oncogenic HPV cellular
transactivator Brn-3a observed in cervical material in this
study suggests that it could be used to predict the early onset
of cervical adenocarcinoma and squamous cell carcinoma.
The few Sarcomatoid squamous cell carcinoma samples
available for this study registered the presence of low but
detectable levels of Brn-3a and HPV E6 mRNA, and so
further work still needs to be done using material obtain
from SSCC biopsies, to investigate what role Brn-3a and the
transactivated viral oncogenic products play in the natural
history of this rare cervical cancer. Thus, studies have shown
that, AC, SCC, and even SSCC share a similar aetiological
profile that hinges on the expressed oncogenic products of
HPV [3, 5–10]. This is in conformity with our findings that,
the Brn-3a cellular transcription factor which specifically
regulates the production of HPV E6 and E7 oncogenes
in cervical cancers could be a pivotal component in the
aetiology of these diseases.
In conclusion, this study suggests that in both in the
developed and developing worlds, the cellular factor Brn-
3a could be used alongside the oncogenic E6 mRNA in the
screening and early diagnosing of both the common and rare
types of cervical cancer.
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